The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
In the last 50 years, 5-fluorouracil-based therapy has been the mainstay of adjuvant and palliative treatment for colorectal cancer but response rates and median survival have been dismal despite the introduction of thymidylate synthase modulators such as leucovorin. Recently, new therapeutic approaches have been introduced. These include oral 5-fluorouracil analogues, pure thymidylate synthase inhibitors, dihydropyrimidine dehydrogenase inhibitors, and agents with mechanism of action unrelated to thymidylate synthase such as irinotecan, a topoisomerase I inhibitor, and oxaliplatin, the only platinum derivative with significant activity in colorectal cancer. Current treatment strategies involve combination therapies because this approach is the most effective. For instance, responses observed with oxaliplatin and 5-fluorouracil indicate synergy between the two agents and the combination of capecitabine plus oxaliplatin or irinotecan has shown high activity both in chemotherapy-naive and in pretreated patients with advanced colorectal cancer. Additionally, it is likely that future therapeutic management of advanced colorectal cancer may include combination therapy of one of the new oral 5-fluorouracil analogues, because of the convenient oral regimens. The identification of colorectal cancer-specific prognostic factors will undoubtedly influence treatment decisions. For instance, patients overexpressing epidermal growth factor receptor and p53 with thymidylate synthase have a worse prognosis. To target these biomarkers, antibodies such as cetuximab, an anti-EGFR antibody, and angiogenesis inhibitors and tyrosine kinase inhibitors have been introduced and are undergoing clinical evaluation. Over the last 5 years the armamentarium to fight colorectal cancer has increased significantly, giving more hope for effective disease management.